Alvotech and Advanz Pharma Expand European Biosimilar Collaboration

Alvotech and Advanz Pharma have announced an expansion of their strategic partnership to include the commercialization of AVT10, a proposed biosimilar to Cimzia® (certolizumab pegol), across Europe. This addition marks the only known biosimilar candidate to Cimzia currently in development globally, targeting chronic rheumatic diseases, particularly in women of childbearing age. 

This agreement builds upon their existing collaboration, which now encompasses biosimilars referencing over ten originator biologics, including treatments for autoimmune and inflammatory diseases. The partnership covers all 30 European Economic Area member countries, as well as the UK and Switzerland, with plans to launch the first biosimilars in Europe starting in Q4 2025. 

Alvotech will oversee the development and manufacturing of AVT10, while Advanz Pharma will handle registration and commercialization efforts. The companies anticipate that this collaboration will enhance patient access to high-quality biologics and support the sustainability of healthcare systems across Europe.